Pulmonary Aspergillosis
Mostrando 25-36 de 146 artigos, teses e dissertações.
-
25. Significance of Aspergillus species isolated from respiratory secretions in the diagnosis of invasive pulmonary aspergillosis.
To determine the significance of Aspergillus species isolated from sputum or other respiratory secretions with respect to the diagnosis of invasive pulmonary aspergillosis, the clinical records and radiographs of all patients whose respiratory secretion cultures yielded an Aspergillus species between 1972 and 1978 were reviewed. All known predispositions to
-
26. Long-Circulating Immunoliposomal Amphotericin B against Invasive Pulmonary Aspergillosis in Mice
We investigated the efficacy of long-circulating immunoliposomal amphotericin B (AmB) against invasive pulmonary aspergillosis in mice using three types of liposomal AmB: conventional liposomal AmB (AmBisome), a long-circulating liposomal AmB and prepared by coating the liposome surface with polyethylene glycol (PEG; PEG-L-AmB), long-circulating immunoliposo
American Society for Microbiology.
-
27. Quantitative Galactomannan Detection Is Superior to PCR in Diagnosing and Monitoring Invasive Pulmonary Aspergillosis in an Experimental Rat Model
Two diagnostic tests, an Aspergillus-specific PCR and an enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of galactomannan, were compared for diagnosing and monitoring invasive pulmonary aspergillosis. Persistently neutropenic rats with left-sided invasive pulmonary aspergillosis were sacrificed at regular intervals after inoculat
American Society for Microbiology.
-
28. Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis.
Mouse models of systemic candidiasis and pulmonary and systemic aspergillosis were established by using DBA/2N mice, which are known to be deficient in the C5 component of complement. In experiments comparing lethality in the respective models in DBA/2N versus outbred CFW mice, results showed that the 50% lethal dose values for the DBA/2N mice were 10- to 1,
-
29. Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease.
Invasive pulmonary aspergillosis usually occurs in severely immunocompromised or neutropenic patients. Six patients with invasive aspergillosis are described whose only defence impairment was underlying lung disease and corticosteroid treatment. Cough, fever, and sputum production were the usual reasons for presentation and four patients developed the sepsis
-
30. Bronchoscopy findings in invasive pulmonary aspergillosis.
Two patients with invasive aspergillosis had unusual endobronchial appearances at fibreoptic bronchoscopy. Diagnosis was achieved by endobronchial biopsy.
-
31. Aspergillus Galactomannan Antigen in the Cerebrospinal Fluid of Bone Marrow Transplant Recipients with Probable Cerebral Aspergillosis
The Aspergillus galactomannan test was performed on cerebrospinal fluid and serum samples from 5 patients with probable cerebral aspergillosis and from 16 control patients. Cerebrospinal fluid galactomannan levels were significantly higher in aspergillosis patients, and most galactomannan was produced intrathecally. Comparison of serum galactomannan values i
American Society for Microbiology.
-
32. Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy.
Three children who developed pulmonary aspergillosis while being treated for leukaemia or non-Hodgkin's lymphoma. Each child continued with intensive myelosuppressive chemotherapy regimens during the infection and each was successfully treated with antifungal prophylaxis based on itraconazole by mouth. Amphotericin B was also given during periods of severe n
-
33. Novel Inhalational Murine Model of Invasive Pulmonary Aspergillosis
We developed a novel model of invasive aspergillosis (IA) that recapitulates human disease. Mice were immunosuppressed with cyclophosphamide and cortisone acetate and then infected in an aerosol chamber. This procedure reproducibly delivered 1 × 103 to 3 × 103 conidia to the lungs. Lethal pulmonary IA developed over 2 weeks and was prevented by amphoterici
American Society for Microbiology.
-
34. Antifungal Activity of the Pradimicin Derivative BMS 181184 in the Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits
The activity of the pradimicin derivative BMS 181184 was evaluated in a model of invasive pulmonary aspergillosis in persistently neutropenic rabbits and compared with that of amphotericin B deoxycholate. BMS 181184 at total daily doses of 50 and 150 mg/kg of body weight was at least as effective as amphotericin B at 1 mg/kg once a day in conferring survival
American Society for Microbiology.
-
35. Evaluation of SCH51048 in an experimental model of pulmonary aspergillosis.
The efficacy of a novel triazole, SCH51048, was assessed with a murine model of pulmonary aspergillosis and was compared with those of SCH39304 and itraconazole. A wide range of doses of SCH51048 (5 to 50 mg/kg of body weight) was evaluated. Mortality was significantly delayed in mice treated with doses of 5 mg of SCH51048 per kg or greater in comparison wit
-
36. Necrotizing pulmonary aspergillosis
Necrotizing or invasive aspergillary infection of the lungs has previously been considered a rare condition affecting only the debilitated or seriously ill. Four patients with necrotizing pulmonary aspergillosis are described, and the mycological and histopathological findings are discussed. The diagnosis in the first patient was not made until necropsy, fol